Literature DB >> 17325347

Evaluation of the vaccine potential of an equine herpesvirus type 1 vector expressing bovine viral diarrhea virus structural proteins.

Cristina T Rosas1, Patricia König, Martin Beer, Edward J Dubovi, B Karsten Tischer, Nikolaus Osterrieder.   

Abstract

Bovine viral diarrhea virus (BVDV) is an economically important pathogen of cattle that is maintained in the population by persistently infected animals. Virus infection may result in reproductive failure, respiratory disease and diarrhoea in naïve, susceptible bovines. Here, the construction and characterization of a novel vectored vaccine, which is based on the incorporation of genes encoding BVDV structural proteins (C, Erns, E1, E2) into a bacterial artificial chromosome of the equine herpesvirus type 1 (EHV-1) vaccine strain RacH, are reported. The reconstituted vectored virus, rH_BVDV, expressed BVDV structural proteins efficiently and was indistinguishable from parental vector virus with respect to growth properties in cultured cells. Intramuscular immunization of seronegative cattle with rH_BVDV resulted in induction of BVDV-specific serum neutralizing and ELISA antibodies. Upon experimental challenge infection of immunized calves with the heterologous BVDV strain Ib SE5508, a strong anamnestic boost of the neutralizing-antibody response was observed in all vaccinated animals. Immunized animals presented with reduced viraemia levels and decreased nasal virus shedding, and maintained higher leukocyte counts than mock-vaccinated controls.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17325347     DOI: 10.1099/vir.0.82528-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  9 in total

1.  Safety and efficacy of an E2 glycoprotein subunit vaccine produced in mammalian cells to prevent experimental infection with bovine viral diarrhoea virus in cattle.

Authors:  Andrea Pecora; María Sol Pérez Aguirreburualde; Alejandra Aguirreburualde; Maria Rosa Leunda; Anselmo Odeon; Sebastián Chiavenna; Diego Bochoeyer; Marcelo Spitteler; Jorge L Filippi; Maria J Dus Santos; Susana M Levy; Andrés Wigdorovitz
Journal:  Vet Res Commun       Date:  2012-05-26       Impact factor: 2.459

2.  Evaluation of a vectored equine herpesvirus type 1 (EHV-1) vaccine expressing H3 haemagglutinin in the protection of dogs against canine influenza.

Authors:  Cristina Rosas; Gerlinde R Van de Walle; Stephan M Metzger; Karin Hoelzer; Edward J Dubovi; Sung G Kim; Colin R Parrish; Nikolaus Osterrieder
Journal:  Vaccine       Date:  2008-03-31       Impact factor: 3.641

Review 3.  Herpesvirus BACs: past, present, and future.

Authors:  Charles Warden; Qiyi Tang; Hua Zhu
Journal:  J Biomed Biotechnol       Date:  2010-10-27

Review 4.  The current status and future directions of myxoma virus, a master in immune evasion.

Authors:  Bart Spiesschaert; Grant McFadden; Katleen Hermans; Hans Nauwynck; Gerlinde R Van de Walle
Journal:  Vet Res       Date:  2011-06-09       Impact factor: 3.683

5.  An equine herpesvirus type 1 (EHV-1) expressing VP2 and VP5 of serotype 8 bluetongue virus (BTV-8) induces protection in a murine infection model.

Authors:  Guanggang Ma; Michael Eschbaumer; Abdelrahman Said; Bernd Hoffmann; Martin Beer; Nikolaus Osterrieder
Journal:  PLoS One       Date:  2012-04-12       Impact factor: 3.240

Review 6.  Viral bacterial artificial chromosomes: generation, mutagenesis, and removal of mini-F sequences.

Authors:  B Karsten Tischer; Benedikt B Kaufer
Journal:  J Biomed Biotechnol       Date:  2012-02-23

7.  An equine herpesvirus type 1 (EHV-1) vector expressing Rift Valley fever virus (RVFV) Gn and Gc induces neutralizing antibodies in sheep.

Authors:  Abdelrahman Said; Mona Elmanzalawy; Guanggang Ma; Armando Mario Damiani; Nikolaus Osterrieder
Journal:  Virol J       Date:  2017-08-14       Impact factor: 4.099

Review 8.  Antigen delivery systems for veterinary vaccine development. Viral-vector based delivery systems.

Authors:  Alejandro Brun; Emmanuel Albina; Tom Barret; David A G Chapman; Markus Czub; Linda K Dixon; Günther M Keil; Bernard Klonjkowski; Marie-Frédérique Le Potier; Geneviève Libeau; Javier Ortego; Jennifer Richardson; Haru-H Takamatsu
Journal:  Vaccine       Date:  2008-12-02       Impact factor: 3.641

Review 9.  Immunoprophylaxis against important virus disease of horses, farm animals and birds.

Authors:  J R Patel; J G M Heldens
Journal:  Vaccine       Date:  2009-03-13       Impact factor: 3.641

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.